News Equillium, Inc.

Equities

EQ

US29446K1060

Delayed Nasdaq Other stock markets 03:02:50 2024-05-20 pm EDT			5-day change	1st Jan Change
1.53 ^USD	-1.92%		-0.65%	+111.62%

May. 14	Equillium, Inc. Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease	CI
May. 09	Earnings Flash (EQ) EQUILLIUM Reports Q1 Revenue $10.7M	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease	May. 14	BU
Equillium, Inc. Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease	May. 14	CI
Earnings Flash (EQ) EQUILLIUM Reports Q1 Revenue $10.7M	May. 09	MT
Equillium, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights	May. 09	BU
Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists	May. 07	BU
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	Apr. 03	BU
H.C. Wainwright Adjusts Price Target on Equillium to $5 From $4, Keeps Buy Rating	Apr. 02	MT
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis	Apr. 01	BU
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1B Equalise Study of Itolizumab in Lupus Nephritis	Apr. 01	CI
Health Care Climbs on Weight-Loss Drug Excitement -- Health Care Roundup	Mar. 26	DJ
Equillium Swings to Q4 Loss As Revenue Falls	Mar. 25	MT
Equillium, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
Equillium, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 25	CI
Earnings Flash (EQ) EQUILLIUM Reports Q4 Revenue $9.2M	Mar. 25	MT
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights	Mar. 25	BU
Equillium to Present at the H.C. Wainwright Autoimmune and Inflammatory Disease Conference and the LD Micro Invitational Conference	Mar. 25	AQ
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference	Mar. 22	BU
EQUILLIUM : 2024 INDUCEMENT PLAN - Form 8-K	Mar. 08	PU
HC Wainwright Adjusts Price Target on Equillium to $4 From $4.50, Keeps Buy Rating	Dec. 26	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Equillium, Inc.

Equities

EQ

US29446K1060

Summary

Filters